Genmab Sees 2025 DARZALEX Sales Hit $14.35B, Buy Rating Reiterated
H.C. Wainwright reiterated a Buy rating on Genmab with a $39 price target following 2025 DARZALEX net sales of $14.351bn, up from $11.670bn in 2024. Genmab earned $2.219bn in first nine months 2025 royalties and now expects full-year royalties to exceed its $2.4bn guidance.
1. Analyst Rating and Price Target
On January 28, H.C. Wainwright reaffirmed a Buy rating on Genmab and maintained a $39 price target, citing strong performance of its flagship product DARZALEX.
2. DARZALEX Net Sales Surge
Worldwide net sales of DARZALEX reached $14.351 billion in 2025, marking a 23% increase from $11.670 billion in 2024, with $8.266 billion sold in the U.S. and $6.085 billion internationally.
3. Royalties Expected to Exceed Guidance
Genmab recorded $2.219 billion in DARZALEX royalties in the first nine months of 2025, up from $1.802 billion a year earlier, and now anticipates full-year royalty income to exceed its $2.4 billion forecast.